IDEAYA Receives Milestones in its Pol Theta Helicase Inhibitor with GSK for Patients Harboring Tumors with BRCA
Shots:
- IDEAYA is eligible to receive ~$485M in development & regulatory milestones, ~$20M in preclinical & clinical milestones to advance Pol Theta helicase DC in early P-I trial, ~$475M in commercial milestones along with royalties
- GSK gets an exclusive license globally to develop and commercialize the Pol Theta helicase inhibitor DC & will be responsible for all R&D costs of the program
- The companies collaborated on IND-enabling studies to support Pol Theta helicase DC in combination with niraparib for patients harboring tumors with BRCA or other HR mutations/HRD. The companies will submit IND for Pol Theta helicase DC to initiate first-in-human studies in H1’23, following the completion of IND-enabling studies
Ref: PRNewswire | Image: IDEAYA
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
